Dividends & Buybacks ·
Arbutus Biopharma announced plans for a modified Dutch auction tender offer to repurchase up to US$230 million of its…
ABUSArbutus Biopharma Corp
Arbutus Biopharma announced plans for a modified Dutch auction tender offer to repurchase up to US$230 million of its common shares at a price between US$5.00 and US$5.75 per share in cash. The transaction is expected to commence around August 24, 2026, and expire on or about September 29, 2026, funded by the company's existing cash reserves. This initiative follows a March 2026 settlement with Moderna and aims to return financial proceeds to shareholders while the company continues legal enforcement of its lipid nanoparticle intellectual property rights against Pfizer and BioNTech. Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on infectious disease treatments.